Related Experiment Video

Updated: May 5, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

12.8K

Towards defining biomarkers indicating resistances to targeted therapies

Franziska Stehle1, Kristin Schulz1, Barbara Seliger1

  • 1Martin Luther University Halle-Wittenberg, Institute of Medical Immunology, Magdeburger Str. 2, D-06112 Halle, Saale, Germany.

Biochimica Et Biophysica Acta
|November 26, 2013
PubMed

Insights

Targeted cancer therapies show promise but often face resistance. Proteomics offers a way to identify biomarkers for predicting and overcoming drug resistance in personalized medicine.

Area of Science:

  • Oncology
  • Proteomics
  • Biomarker Discovery

Background:

  • Targeted therapies yield initial tumor responses but acquired resistance limits efficacy.
  • Mechanisms of resistance include genetic alterations, protein expression changes, and tumor heterogeneity.
  • Biomarkers are crucial for cancer prognosis and personalized treatment strategies.

Purpose of the Study:

  • To review the implementation of proteome-based analysis for identifying resistance mechanisms.
  • To highlight the role of proteomics in stratifying patients and optimizing targeted therapies.
  • To discuss proteomic biomarkers for predicting and overcoming drug resistance.

Main Methods:

  • Review of existing literature on targeted therapies and resistance mechanisms.
  • Focus on "ome"-based technologies, particularly proteomics.
  • Analysis of proteomic data for pathway (in)activation markers.

Main Results:

  • Proteomics can identify specific markers associated with intrinsic and acquired resistance.
  • Proteomic profiling aids in categorizing resistance mechanisms across different tumor types.
  • Identification of biomarkers can guide the selection of combination treatment strategies.

Conclusions:

  • Proteome-based analysis is a valuable tool for understanding and overcoming drug resistance.
  • Biomarkers identified through proteomics enable personalized cancer medicine.
  • Optimizing individually tailored therapies relies on robust biomarker discovery.
Keywords:
ProteomicsTargeted therapyTyrosine kinase inhibitor

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

6.5K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

6.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
129